Literature DB >> 16368569

Laboratory analysis of T-cell immunity.

Keith L Knutson1, Corazon dela Rosa, Mary Lenora Disis.   

Abstract

Immune-based strategies for treating and preventing cancer are increasingly being tested and include cancer vaccination, adoptive T cell therapy, and cytokine therapy. An important component of testing and development of immune-based strategies is monitoring the immunologic response. The ability to monitor T cell immunity has been suboptimal. The measurement of tumor-specific immunity will aid in defining which strategies should be moved forward in clinical trials and which should be eliminated or evaluated further in the preclinical realm. Immunologic monitoring is necessary for determining if an approach has immunologic efficacy and ultimately whether immunologic responses correlate with a clinical response. This article discusses several important elements of measuring T cell immunity such as validation principles, laboratory issues, current approaches, and new paradigms and concepts for future testing. Informative immunologic monitoring of T cells will be one of the driving forces in advancing the field of tumor immunology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368569     DOI: 10.2741/1936

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.

Authors:  Ameya Gokhale; Thomas K Weldeghiorghis; Veena Taneja; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

2.  Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Authors:  Kimberly R Kalli; Matthew S Block; Pashtoon M Kasi; Courtney L Erskine; Timothy J Hobday; Allan Dietz; Douglas Padley; Michael P Gustafson; Barath Shreeder; Danell Puglisi-Knutson; Dan W Visscher; Toni K Mangskau; Glynn Wilson; Keith L Knutson
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

3.  Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein Interaction.

Authors:  Rushikesh Sable; Thomas Durek; Veena Taneja; David J Craik; Sandeep Pallerla; Ted Gauthier; Seetharama Jois
Journal:  ACS Chem Biol       Date:  2016-07-01       Impact factor: 5.100

4.  Peptide:MHC tetramer-based enrichment of epitope-specific T cells.

Authors:  Francois P Legoux; James J Moon
Journal:  J Vis Exp       Date:  2012-10-22       Impact factor: 1.355

5.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12

6.  No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.

Authors:  Janet W de Beukelaar; Georges M Verjans; Yvette van Norden; Johannes C Milikan; Jaco Kraan; Herbert Hooijkaas; Kees Sintnicolaas; Jan W Gratama; Peter A Sillevis Smitt
Journal:  Cancer Immunol Immunother       Date:  2007-02-14       Impact factor: 6.968

7.  Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses.

Authors:  Vivian Goodell; Corazon dela Rosa; Meredith Slota; Beth MacLeod; Mary L Disis
Journal:  BMC Immunol       Date:  2007-09-12       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.